Kiotech encouraged by trading

Kiotech, the developer of technology that mimics chemical signals secreted or released by organisms, said its trading performance at the half-year stage has been "most encouraging".The integration of the Optivite acquisition has gone well with the consolidation of operations starting to deliver the planned benefits. There are a number of integration projects still underway and these to be completed before the year-end. International trading has been good and in the UK the company has been re-structuring its sales and operations team to focus on those customer segments where it expects to have the most success. Cash at the end of June stood at £4.6m.